T‐cell‐mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis

Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test

“…Delayed hypersensitivity reactions have been reported since the introduction of CFTR modulators in 2019 [2]. Few clinical cases had an allergy study using lymphocyte clone cultures to demonstrate T cell-mediated hypersensitivity [6]. In our case, we obtained a positive result in the LTT with IVA and the three components ETI, being even more positive with the latter and, therefore, without being able to rule out the involvement of the other two active ingredients.…”

Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis

“…However, rigorous studies to support these conclusions are lacking ( Thong and Tan, 2011 ). In patients where antibiotic courses are often given frequently and in high doses, such as in cystic fibrosis, the incidence of drug hypersensitivity is high ( Pirmohamed et al , 2015 ; Roehmel et al , 2014 ; Semic-Jusufagic et al , 2022 ). Moreover, studies showed that high doses of phenytoin, particularly at commencement of the therapy, can increase the risk of cutaneous eruptions ( Wilson et al , 1978 ).…”